小鼠模型中抗体介导的MERS-CoV保护作用
研究用RBD-Fc融合蛋白经皮下初免和口服加强免疫Balb/c小鼠,诱导出对两株MERS-CoV临床分离株完全中和的抗血清。经Ad5-hDPP4转导使小鼠易感后被动转移该抗血清,鼻内攻毒显示肺部病毒载量较阴性对照抗体组显著降低。
要点
- RBD-Fc经磷酸钙微晶吸附皮下初免、反向胶束口服加强可诱导全身和黏膜抗病毒免疫。
- 该抗血清在体外对两株MERS-CoV临床分离株呈完全中和。
- 被动转移后鼻内攻毒,转导小鼠肺部病毒载量较阴性对照抗体组显著降低。
核心结论
- RBD-Fc双途径接种诱导的鼠抗血清在体外和体内均对MERS-CoV临床株具有中和能力。
研究设计与样本
- Balb/c小鼠以RBD-Fc(吸附于磷酸钙微晶)皮下初免、反向胶束口服加强,制备抗血清。
- 经Ad5-hDPP4转导使naive Balb/c受鼠易感,被动转移RBD特异性鼠抗血清后鼻内攻毒MERS-CoV临床分离株。
主要发现
- 所诱导鼠抗血清对两株MERS-CoV临床分离株在体外呈完全中和。
- 攻毒后转导受鼠肺部病毒载量较接受阴性对照抗体的转导小鼠显著降低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Murine antisera with neutralising activity for the coronavirus causative of Middle East respiratory syndrome (MERS) were induced by immunisation of Balb/c mice with the receptor binding domain (RBD) of the viral Spike protein. The murine antisera induced were fully-neutralising in vitro for two separate clinical strains of the MERS coronavirus (MERS-CoV). To test the neutralising capacity of these antisera in vivo, susceptibility to MERS-CoV was induced in naive recipient Balb/c mice by the administration of an adenovirus vector expressing the human DPP4 receptor (Ad5-hDPP4) for MERS-CoV, prior to the passive transfer of the RBD-specific murine antisera to the transduced mice. Subsequent challenge of the recipient transduced mice by the intra-nasal route with a clinical isolate of the MERS-CoV resulted in a significantly reduced viral load in their lungs, compared with transduced mice receiving a negative control antibody. The murine antisera used were derived from mice which had been primed sub-cutaneously with a recombinant fusion of RBD with a human IgG Fc tag (RBD-Fc), adsorbed to calcium phosphate microcrystals and then boosted by the oral route with the same fusion protein in reverse micelles. The data gained indicate that this dual-route vaccination with novel formulations of the RBD-Fc, induced systemic and mucosal anti-viral immunity with demonstrated in vitro and in vivo neutralisation capacity for clinical strains of MERS-CoV.
引用
- New RRC, Moore BD, Butcher W, et al. Antibody-mediated protection against MERS-CoV in the murine model. Vaccine. 2019. PMID: 31178378. doi:10.1016/j.vaccine.2019.05.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。